Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance

Abstract Despite decades of research, glioblastoma (GBM) remains invariably fatal among all forms of cancers. The high level of inter‐ and intratumoral heterogeneity along with its biological location, the brain, are major barriers against effective treatment. Molecular and single cell analysis iden...

Full description

Bibliographic Details
Main Authors: Zulfikar Azam, Shing‐Shun Tony TO, Bakhos A. Tannous
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:Advanced Science
Subjects:
Online Access:https://doi.org/10.1002/advs.202002015
id doaj-40ec1918116a4fb3896d28a1646b5c7f
record_format Article
spelling doaj-40ec1918116a4fb3896d28a1646b5c7f2020-11-25T04:10:44ZengWileyAdvanced Science2198-38442020-11-01722n/an/a10.1002/advs.202002015Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy ResistanceZulfikar Azam0Shing‐Shun Tony TO1Bakhos A. Tannous2Experimental Therapeutics and Molecular Imaging Unit Department of Neurology Neuro‐Oncology Division Massachusetts General Hospital and Harvard Medical School Boston MA 02129 USADepartment of Health Technology and Informatics The Hong Kong Polytechnic University Hong Kong 999077 ChinaExperimental Therapeutics and Molecular Imaging Unit Department of Neurology Neuro‐Oncology Division Massachusetts General Hospital and Harvard Medical School Boston MA 02129 USAAbstract Despite decades of research, glioblastoma (GBM) remains invariably fatal among all forms of cancers. The high level of inter‐ and intratumoral heterogeneity along with its biological location, the brain, are major barriers against effective treatment. Molecular and single cell analysis identifies different molecular subtypes with varying prognosis, while multiple subtypes can reside in the same tumor. Cellular plasticity among different subtypes in response to therapies or during recurrence adds another hurdle in the treatment of GBM. This phenotypic shift is induced and sustained by activation of several pathways within the tumor itself, or microenvironmental factors. In this review, the dynamic nature of cellular shifts in GBM and how the tumor (immune) microenvironment shapes this process leading to therapeutic resistance, while highlighting emerging tools and approaches to study this dynamic double‐edged sword are discussed.https://doi.org/10.1002/advs.202002015clinical outcomeglioblastoma (GBM)mesenchymal transitionmolecular subtypestherapy responsestumor microenvironment
collection DOAJ
language English
format Article
sources DOAJ
author Zulfikar Azam
Shing‐Shun Tony TO
Bakhos A. Tannous
spellingShingle Zulfikar Azam
Shing‐Shun Tony TO
Bakhos A. Tannous
Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance
Advanced Science
clinical outcome
glioblastoma (GBM)
mesenchymal transition
molecular subtypes
therapy responses
tumor microenvironment
author_facet Zulfikar Azam
Shing‐Shun Tony TO
Bakhos A. Tannous
author_sort Zulfikar Azam
title Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance
title_short Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance
title_full Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance
title_fullStr Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance
title_full_unstemmed Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance
title_sort mesenchymal transformation: the rosetta stone of glioblastoma pathogenesis and therapy resistance
publisher Wiley
series Advanced Science
issn 2198-3844
publishDate 2020-11-01
description Abstract Despite decades of research, glioblastoma (GBM) remains invariably fatal among all forms of cancers. The high level of inter‐ and intratumoral heterogeneity along with its biological location, the brain, are major barriers against effective treatment. Molecular and single cell analysis identifies different molecular subtypes with varying prognosis, while multiple subtypes can reside in the same tumor. Cellular plasticity among different subtypes in response to therapies or during recurrence adds another hurdle in the treatment of GBM. This phenotypic shift is induced and sustained by activation of several pathways within the tumor itself, or microenvironmental factors. In this review, the dynamic nature of cellular shifts in GBM and how the tumor (immune) microenvironment shapes this process leading to therapeutic resistance, while highlighting emerging tools and approaches to study this dynamic double‐edged sword are discussed.
topic clinical outcome
glioblastoma (GBM)
mesenchymal transition
molecular subtypes
therapy responses
tumor microenvironment
url https://doi.org/10.1002/advs.202002015
work_keys_str_mv AT zulfikarazam mesenchymaltransformationtherosettastoneofglioblastomapathogenesisandtherapyresistance
AT shingshuntonyto mesenchymaltransformationtherosettastoneofglioblastomapathogenesisandtherapyresistance
AT bakhosatannous mesenchymaltransformationtherosettastoneofglioblastomapathogenesisandtherapyresistance
_version_ 1724419358297423872